前列舒通胶囊联合非那雄胺片治疗良性前列腺增生的Meta分析  

Meta-analysis of Qianlie Shutong Capsule combined with finasteride tablets in the treatment of benign prostatic hyperplasia

作　　者：黄登霞 张春和 傅伟[2] 于欣 杨宁 肖子浩 王慧 黄文杰[4] 杨毅坚 HUANG Dengxia;ZHANG Chunhe;FU Wei;YU Xin;YANG Ning;XIAO Zihao;WANG Hui;HUANG Wenjie;YANG Yijian(Department of Andrology,the First Clinical College of Yunnan University of Chinese Medicine(the First Affiliated Hospital of Yunnan University of Chinese Medicine),Kunming650021,Yunnan,China;Department of Andrology,the Seventh Clinical College of Guangzhou University of Chinese Medicine,Guangzhou 510006,Guangdong,China;Department of Proctology,the Second Affiliated Hospital of Guizhou University of Chinese Medicine,Guiyang550003,Guizhou,China;Department of Urology,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou310017,Zhejiang,China)

机构地区：[1]云南中医药大学第一临床医学院(云南中医药大学第一附属医院)男科,昆明650021 [2]广州中医药大学第七临床医学院男科,广州510006 [3]贵州中医药大学第二附属医院肛肠科,贵阳550003 [4]浙江大学医学院附属第二医院泌尿外科,杭州310017

出　　处：《中国性科学》2023年第9期29-35,共7页Chinese Journal of Human Sexuality

基　　金：国家自然科学基金地区科学基金项目(81860853);国家自然科学基金面上项目(81774323);浙江省中医药科学研究基金项目(A类,2021ZA068)。

摘　　要：目的采用Meta分析观察前列舒通胶囊联合非那雄胺片治疗良性前列腺增生(BPH)的临床有效性和安全性。方法检索the Cochrane Library、中国生物医学文献、PubMed、中国知网、维普、万方等数据库建库至2022年5月1日收录的前列舒通胶囊联合非那雄胺片治疗BPH的随机对照试验(RCT),并进行方法学质量评价,采用RevMan 5.4软件进行统计分析,进行发表偏倚评估。结果共9篇RCT纳入本研究,累计病例697例。Meta分析结果显示,前列舒通胶囊联合非那雄胺片治疗BPH的总有效率(OR=4.81,95%CI:2.66~8.70,P<0.00001)、最大尿流率(MD=2.94,95%CI:1.40~4.48,P=0.0002)、膀胱残余尿量(MD=-9.11,95%CI:-11.95~-6.27,P<0.00001)、前列腺体积(MD=-5.36,95%CI:-6.76~-3.96,P<0.00001)、国际前列腺症状评分(MD=-5.42,95%CI:-7.07~-3.76,P<0.00001)均显著优于单纯使用非那雄胺片治疗。结论前列舒通胶囊联合非那雄胺片治疗BPH的疗效确切,且优于单纯使用非那雄胺片治疗,是中西医联合用药治疗BPH的有效方法。Objective To observe the clinical efficacy and safety of Qianlie Shutong Capsule combined with finasteride tablets in the treatment of benign prostatic hyperplasia(BPH)by Meta-analysis.Methods The Cochrane Library,China Biomedical Literature database,PubMed database,China National Knowledge Infrastructure(CNKI)database,China Science and Technology Journal(VIP)database and Wanfang database were searched.Randomized controlled trials(RCTs)of Qianlie Shutong Capsule combined with finasteride tablets in the treatment of BPH from inception to May 1,2022 were included,and the methodological quality was evaluated.RevMan 5.4 software was used for statistical analysis,and publication bias was assessed.Results A total of 9 RCTs were included in this study,with a total of 697 cases.The results of Meta-analysis showed that the total effective rate(OR=4.81,95%CI:2.66-8.70,P0.000,01)and the maximum urinary flow rate(MD=2.94,95%CI:1.40-4.48,P0.000,2),bladder residual urine volume(MD=-9.11,95%CI:-11.95--6.27,P0.000,01),prostate volume(MD=-5.36,95%CI:-6.76--3.96,P0.000,01)and international prostate symptom score(IPSS)score(MD=-5.42,95%CI:-7.07--3.76,P0.000,01)were significantly better than those of finasteride tablets group.Conclusions The combination of Qianlie Shutong Capsule combined with finasteride tablets is effective in the treatment of BPH,which is superior to treating with finasteride tablets alone.It is an effective method of combined traditional Chinese medicine and western medicine in the treatment of BPH.

关 键 词：前列舒通胶囊 非那雄胺片 良性前列腺增生 META分析 

分 类 号：R277.5[医药卫生—中医学]